Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movements. Its symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. However, the disease can be controlled by a healthy lifestyle and medication.

The Dyskinesia pipeline market research report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Key Targets in the Dyskinesia Pipeline Products Market

The key targets in the Dyskinesia pipeline products market are Synaptosomal Associated Protein 25, Synaptic Vesicular Amine Transporter, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, Metabotropic Glutamate Receptor 5, Voltage Dependent T Type Calcium Channel, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 1B, Cannabinoid Receptor 1, Cannabinoid Receptor 2, and others.

Dyskinesia Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Dyskinesia Pipeline Products Market

The key mechanisms of action in the Dyskinesia pipeline products market are Synaptosomal Associated Protein 25 Inhibitor, Synaptic Vesicular Amine Transporter Inhibitor, 5-Hydroxytryptamine Receptor 1A Agonist, Metabotropic Glutamate Receptor 5 Antagonist, Voltage Dependent T Type Calcium Channel Blocker, 5-Hydroxytryptamine Receptor 1B Agonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Gamma-Aminobutyric Acid Type A Receptor Subunit GABAAgonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, and others.

Dyskinesia Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Dyskinesia Pipeline Products Market

The key routes of administration in the Dyskinesia pipeline products market are oral, intramuscular, intradermal, parenteral, subcutaneous, topical, intraarticular, intraprostatic, sublingual, and transdermal.

Dyskinesia Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Dyskinesia Pipeline Products Market

The key molecule types in the Dyskinesia pipeline products market are small molecule, protein, recombinant protein, RNAi gene therapy, and synthetic peptide.

Dyskinesia Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the Dyskinesia Pipeline Products Market

Some of the major companies in the Dyskinesia pipeline products market are Neurocrine Biosciences Inc, Contera Pharma ApS, Jazz Pharmaceuticals Plc, Addex Therapeutics Ltd, Ipsen SA, Neuralina Therapeutics Inc, Revance Therapeutics Inc, SalubRx Therapeutics Inc, SOM Biotech SL, and AfaSci Inc.

Dyskinesia Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Dyskinesia Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.